Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Rana M Abd Elhameed, Resident
- Phone Number: 01070198923
- Email: rana_mohamed_post@med.sohag.edu.eg
Study Contact Backup
- Name: Eman H Ali, Assistant Professor
Study Locations
-
-
Sahag
-
Sohag, Sahag, Egypt
- Recruiting
- Sohag university hospital
-
Contact:
- Magdy M Ameen, Professor
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with platelet less than 100 × 109/L diagnosed as immune thrombocytopenia by bone marrow findings .
Age of patients : from 1 year to 50 years.
Exclusion Criteria:
- Other causes of thrombocytopenia as:
- Hypersplenism.
- Bone marrow diseases including : aplastic anemia, leukemia and myelodysplastic syndromes.
- Cancer treatments like chemotherapy and radiation therapy.
- Exposure to toxic chemicals as arsenic and benzene.
- Medications to treat bacterial infections (antibiotics)and treat seizures or blood thinner heparin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: age and sex matched thrombocytopenic patients other than ITP.
Causes of decreased platelets count other than immune thrombocytopenia
|
Assessment of acute phase proteins levels in patients diagnosed with immune thrombocytopenia
|
|
Active Comparator: acute ITP patients
Patients diagnosed as acute thrombocytopenia
|
Assessment of acute phase proteins levels in patients diagnosed with immune thrombocytopenia
|
|
Active Comparator: chronic ITP patients .
Patients diagnosed as chronic thrombocytopenia
|
Assessment of acute phase proteins levels in patients diagnosed with immune thrombocytopenia
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute phase proteins
Time Frame: 2 years
|
By taking serum samples from pateints and measure acute phase proteins levels
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Gruys E, Toussaint MJ, Niewold TA, Koopmans SJ. Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B. 2005 Nov;6(11):1045-56. doi: 10.1631/jzus.2005.B1045.
- Zeller B, Rajantie J, Hedlund-Treutiger I, Tedgard U, Wesenberg F, Jonsson OG, Henter JI; NOPHO ITP. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr. 2005 Feb;94(2):178-84. doi: 10.1111/j.1651-2227.2005.tb01887.x.
- Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011 Apr;11(4):264-74. doi: 10.1038/nri2956.
- Sullivan PS, Hanson DL, Chu SY, Jones JL, Ciesielski CA. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 1;14(4):374-9. doi: 10.1097/00042560-199704010-00011. Erratum In: J Acquir Immune Defic Syndr Hum Retrovirol 1997 May 1;15(1):94.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cytopenia
- Pathologic Processes
- Autoimmune Diseases
- Immune System Diseases
- Hemorrhage
- Skin Manifestations
- Hematologic Diseases
- Blood Coagulation Disorders
- Hemorrhagic Disorders
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura, Thrombocytopenic
- Purpura
- Thrombocytopenia
- Purpura, Thrombocytopenic, Idiopathic
Other Study ID Numbers
Other Study ID Numbers
- Soh-Med-24-11-13MS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.